What is the role of valrubicin in bladder carcinoma in situ treatment?

Updated: Oct 24, 2019
  • Author: Stanley A Brosman, MD; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print


Valrubicin has been approved as intravesical chemotherapy for CIS that is refractory to BCG. [9] In patients whose conditions do not respond to BCG, the overall response rate to valrubicin is approximately 20%. In some patients, valrubicin chemotherapy can delay time to cystectomy. Valrubicin is currently not commercially available.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!